Unlike most antibodies to #SARSCoV2, which target the virus spike protein's receptor binding domain, a newly discovered antibody neutralizes the virus by binding the spike protein's N-terminal domain. May lead to promising "cocktail" antibody therapeutics
Unlike most antibodies to #SARSCoV2, which target the virus spike protein's receptor binding domain, a newly discovered antibody neutralizes the virus by binding the spike protein's N-terminal domain. May lead to promising "cocktail" antibody therapeutics
Unlike most antibodies to #SARSCoV2, which target the virus spike protein's receptor binding domain, a newly discovered antibody neutralizes the virus by binding the spike protein's N-terminal domain. May lead to promising "cocktail" antibody therapeutics
#NeutralizingAntibody to #SARSCoV2 | binds to the N-terminal domain (NTD) of the Spike protein and not to the RBD | Binding profiles | Wei Chen Beijing Institute of Biotechnology
#NeutralizingAntibody to #SARSCoV2 | binds to the N-terminal domain (NTD) of the Spike protein and not to the RBD | Isolation from convalescent patients | Wei Chen Beijing Institute of Biotechnology
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
#NeutralizingAntibody to #SARSCoV2 | binds to the N-terminal domain (NTD) of the Spike protein and not to the RBD | Wei Chen Beijing Institute of Biotechnology
#NeutralizingAntibody to #SARSCoV2 | binds to the N-terminal domain (NTD) of the Spike protein and not to the RBD | Binding profiles | Wei Chen Beijing Institute of Biotechnology | #2020_ReCapJune